Pseudo-Bartter syndrome in a neonate on prostaglandin infusion.
We describe a case of iatrogenic pseudo-Bartter syndrome caused by administration of prostaglandin E1 (PGE1 alprostadil). Although the use of i.v. PGE1 is a well-established pharmacological therapy in neonates with a ductus-dependent congenital cardiopathy to ensure ductus-dependent flow, we could only find one other report on pseudo-Bartter syndrome related to PGE1 infusion.


CONCLUSIONS
Primary Bartter syndrome is associated with endogenous increased levels of prostaglandins. Therefore, we postulate that the dose of prostaglandin E1 administered, immaturity and the genetic background are all relevant factors involved in the phenotypic presentation of iatrogenic pseudo-Bartter syndrome in this preterm infant.
Vanhaesebrouck
Sofie
S
Neonatal Intensive Care Unit, Department of Paediatrics, University Hospitals Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.
Allegaert
Karel
K
Vanhole
Christine
C
Devlieger
Hugo
H
Gewillig
Marc
M
Proesmans
Willem
W
D000015:Abnormalities, Multiple / Q000175:diagnosis / Q000188:drug therapy; D000527:Alprostadil / Q000008:administration & dosage* / Q000009:adverse effects*; D001477:Bartter Syndrome / Q000139:chemically induced*; D004310:Double Outlet Right Ventricle / Q000175:diagnosis / Q000188:drug therapy; D004374:Ductus Arteriosus, Patent / Q000175:diagnosis / Q000188:drug therapy; D004452:Echocardiography; D006801:Humans; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D008297:Male; D009318:Natriuresis / Q000187:drug effects; D011141:Polyuria / Q000139:chemically induced; D011662:Pulmonary Subvalvular Stenosis / Q000151:congenital / Q000175:diagnosis / Q000188:drug therapy; D013577:Syndrome; D014188:Transposition of Great Vessels / Q000175:diagnosis / Q000188:drug therapy; D017211:Treatment Failure; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects*
D014665:Vasodilator Agents; D000527:Alprostadil